Cargando…
Phase II Evaluation of VDC‐1101 in Canine Cutaneous T‐Cell Lymphoma
BACKGROUND: Canine cutaneous T‐cell lymphoma (CTCL) is an uncommon disease for which efficacious therapies are lacking. The novel anticancer nucleotide prodrug VDC‐1101 (formerly known as GS‐9219) has shown efficacy in dogs with multicentric lymphoma. One of the observed adverse effects with this dr...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895598/ https://www.ncbi.nlm.nih.gov/pubmed/25274443 http://dx.doi.org/10.1111/jvim.12429 |